Citi analyst David Lebowitz upgraded Blueprint Medicines (NASDAQ: BPMC) from to Neutral with a price target of $129.00 (from $83.00).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE